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Background. Iron overload syndromes include a wide spectrum of genetic and acquired 
conditions. Recent studies suggest suppressed hepcidin synthesis in the liver to be the molecular 
basis of hemochromatosis. However, a liver with acquired iron overload synthesizes an adequate 
amount of hepcidin. Thus, hepcidin could function as a biochemical marker for differential 
diagnosis of iron overload syndromes. 
Methods. We measured serum iron parameters and hepcidin-25 levels followed by sequencing 
HFE, HJV, HAMP, TFR2, and SLC40A1 genes in 13 Japanese patients with iron overload 
syndromes. In addition, we performed direct measurement of serum hepcidin-25 levels using 
liquid chromatography–tandem mass spectrometry in 3 Japanese patients with 
aceruloplasminemia and 4 Italians with HFE-hemochromatosis. 
Results. One patient with HJV-hemochromatosis, 2 with TFR2-hemochromatosis, and 3 with 
ferroportin disease were found among the 13 Japanese patients. The remaining 7 Japanese 
patients showed no evidence for genetic basis of iron overload syndrome. As far as the serum 
hepcidin-25 was concerned, seven patients with hemochromatosis and 3 with 
aceruloplasminemia showed markedly decreased serum hepcidin-25 levels. In contrast, 3 patients 
with ferroportin disease and 7 with secondary iron overload syndromes showed serum hepcidin 
levels parallel to their hyperferritinemia. Patients with iron overload syndromes were divided 
into 2 phenotypes presenting as low and high hepcidinemia. These were then associated with 
their genotypes. 
Conclusion. Determining serum hepcidin-25 levels may aid differential diagnosis of iron 
overload syndromes prior to genetic analysis. (231 words) 
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Hemochromatosis is caused by inadequate iron absorption leading to excessive body 
iron stores. If left undetected and untreated, progressive iron overload may independently lead to 
cirrhosis, diabetes mellitus (DM), cardiac failure, and endocrine disorders. Hemochromatosis 
includes HFE-hemochromatosis mainly from the C282Y/C282Y mutation in HFE.1 Non-HFE 
hemochromatosis is associated with the hemojuvelin (HJV),2 human antimicrobial peptide 
(HAMP),3 and transferrin receptor 2 (TFR2)4 genes. Evidence suggests the crucial role played by 
the hormone hepcidin, encoded by HAMP, in hemochromatosis. Hepcidin was first identified as 
an antimicrobial peptide synthesized in the liver and excreted in the urine.5, 6 Subsequent animal 
model studies indicated a close association of hepcidin with iron overload.7, 8 Hepcidin forms a 
complex with the transmembrane iron exporter protein of ferroportin; the complex is then 
internalized, and degraded in reticuloendothelial cells and enterocytes.9 Thus, hepcidin regulates 
body iron levels by functionally suppressing ferroportin. Pathological inflammation also 
increases hepcidin synthesis,8, 10 while erythropoietic activity decreases it.11 However, regardless 
of body iron overload, hepcidin mRNA expression in the liver is suppressed in patients with 
hemochromatosis,12 resulted in decreased urinary output of hepcidin.2, 13, 14 Evidence suggests 
that functional disruption of the hepcidin system might be a molecular basis for 
hemochromatosis, but few reports on the active form of serum hepcidin-25 have been published 
to date owing to the lack of reliable methods for quantitative determination.15, 16, 17 
Aceruloplasminemia is a neurological disorder characterized by heavy iron overload in 
the liver and brain with clinical manifestations of ataxia, involuntary movement, retinal 
degeneration, and dementia around the age of 50.18 It results from a mutation in the 
ceruloplasmin gene (CP).19 Ceruloplasmin encoded by CP is a major ferroxidase in circulation, 
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and is believed to play a crucial role in maintaining stability of cell surface ferroportin.20 
Impaired regulation of ceruloplasmin negatively impacts ferroportin expression, which in turn  
blocks iron transport in patients. 
Ferroportin disease has been recently identified as a genetic iron overload syndrome. 
The disease is inherited as an autosomal dominant trait,21, 22 and occurs in populations throughout 
the world.23, 24, 25 Patients with a major form of ferroportin disease (type A) present with 
macrophage iron deposition and high ferritin levels despite normal transferrin saturation.21, 22 In 
contrast, patients with the minor form (type B) develop abnormalities, such as elevated 
transferrin saturation and a more severe, mixed iron overload in parenchymal and 
reticuloendothelial cells similar to typical hemochromatosis.23, 26 It is interesting that the urinary 
output of hepcidin increases in type A27 and is normal in type B ferroportin disease.28 
Transfusions and parenteral iron supplements are relatively frequent causes of secondary 
iron overload in patients with refractory anemia. Before the clinical introduction of 
erythropoietin, the anemia associated with chronic renal failure (CRF) was treated with 
transfusions or inadequate iron supplements leading to a variety of hyperferritinemias.29 Patients 
with chronic hepatitis C (CHC) may also face complications with parenchymal cell iron overload 
in the liver.30 Iron overload is frequently observed in patients with alcoholic liver disease (ALD) 
or nonalcoholic steatohepatitis (NASH).31 Thus, some patients with anemia, CRF, CHC, ALD, 
and NASH present with hyperferritinemia and liver iron deposition mimicking hemochromatosis 
and hence, require a differential diagnosis from genetic iron overload conditions. The liver with 
acquired iron overload can synthesize an appropriate amount of hepcidin. Therefore, direct 
measurement of serum hepcidin-25 levels could differentiate acquired iron overload from its 
genetic form, and also confirm results from current investigations, which are based on either 
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hepcidin mRNA expression in the liver or urinary output of hepcidin. Of the 3 types of hepcidin 
molecules, namely hepcidins-20, -22, and -25, the active form that binds to ferroportin is 
hepcidin-25.32 In this study, we evaluated serum hepcidin-25 levels as a biochemical marker to 
differentiate among iron overload disorders in 20 patients with established genetic basis of iron 
overload syndrome. 




Twenty patients were enrolled in this study and were divided into 3 groups. The first 
group comprised of 13 Japanese patients who were referred to 2 institutes in central Japan 
(Kanazawa University Hospital and Aichi Gakuin University) between January 1998 and 
December 2009 for a genetic study of patients with iron overload syndromes. The second group 
comprised of 3 Japanese patients with aceruloplasminemia. Their condition had been effectively 
managed post diagnosis at Hamamatsu University Hospital. The clinical diagnosis of the 3 
patients with aceruloplasminemia was confirmed by gene analyses for CP 19 as per procedures 
approved by the ethics committees of Hamamatsu University (No. HUH 21-91) before the entry 
time of February of 2008 for direct determination of serum hepcidin-25. The third group 
comprised 4 of Italian patients who were randomly selected from an HFE hemochromatosis 
database at the University of Milano–Bicocca. All patients gave their informed written consent to 
genetic testing, measurement of all biochemical markers including serum hepcidine-25 levels 
and treatment according to the Declaration of Helsinki. 
A biochemical study including determination of serum hepcidin-25 levels as well as a 
genetic analysis (prediagnostic fresh sampling) were performed in the first group of patients. The 
inclusion criterion was a biochemical iron overload twice as high as the normal range for serum 
ferritin levels (normal for male: 26–310 ng/mL; females: 7–110 ng/mL). The exclusion criterion 
was anemia less than 11.0 g/dL. Other biochemical tests included the measuring hemoglobin, 
serum iron levels, and iron-binding capacity. Transferrin saturation was estimated by the standard 
method: serum iron (g/dL)/iron-binding capacity (g/dL) multiplied by 100. 
The genes analyzed in the first group of patients included HFE, TFR2, HJV, HAMP, and 
SLC40A1.25, 33, 34 Informed consent was obtained from each patient, and the protocol was 
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approved by the ethics committees of 2 institutes (Kanazawa University Hospital, No. 2004-66; 
and Aichi Gakuin University, Nos. 6 and 8). And the protocol was approved by the ethics 
committees of 2 institutes (Kanazawa University Hospital, No. 2004-66; and Aichi Gakuin 
University, Nos. 6 and 8). 
In aceruloplasminemia patients, fresh sera for measuring serum hepcidin-25 levels were 
sampled between January and February 2008, during the post diagnosis management period. Iron 
overload persisted in these patients because of intolerance to phlebotomy treatment (fresh 
sampling during treatment). Long-term frozen sera obtained from the third group of Italian 
patients during the pre- and post-treatment periods were sent from Italy to an institute in Japan in 
February 2008 followed by measuring serum hepcidin-25 levels (long-term frozen sera). 
Biochemical variables including serum hepcidin-25 levels were determined during 
phlebotomy treatment in 4 patients (cases 3, 5, 18, and 20). 
 
Quantification of serum hepcidin-25 by LC tandem MS. 
 Sera from all patients were frozen and stored at −80 °C until analysis. Serum 
hepcidin-25 levels were determined using a liquid chromatography–tandem mass 
spectrometry-based assay system.35, 36 Rat serum spiked with human synthetic hepcidin-25 
(MW2789, Peptide Inc., Minoh-shi, Japan) was used to obtain 1, 2, 4, 8, 16, 32, 64, and 128 
ng/mL standards. Synthetic isotopic human hepcidin-25 (MW2830; Peptide Institute) was added 
to each diluted sample and to the standards as an internal standard. The samples and standards 
were then injected onto a 150  2.1 mm PLRP-S column packed with 5-mm particles with a 
300-Å pore size (Varian Inc., CA, USA) for LC (Prominence LC20-ADvp; Shimadzu, Kyoto, 
Japan). The column eluent was connected to an ion spray source on a hybrid triple-quadrupole 
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linear ion trap system (400 QTRAP LC/MS/MS System; Applied Biosystems, Foster City, CA, 
USA). A standard curve was generated to determine the mass spectrometer response for human 
synthetic hepcidin-25 under the described assay conditions. The curve was found to be linear 
from 1.0 to 128 ng/mL, (y = 0.008x + 0.002, r = 0.998). Intraassay and interassay CVs were 
<6.7% and <8.8%, respectively. The lower limit of detection was 1.0 ng/mL with a signal to 
noise ratio of 10:1. 
 
Statistical analysis 
 All pretreatment biochemical data were expressed as mean ± SD. Statistical analysis 
was performed using the nonparametric test (Spearman's rank method) to determine the strength 
of a correlation between serum ferritin and serum hepcidin-25 level.  




 Patient profiles and laboratory data at entry are indicated in Table 1. The serum ferritin 
levels were 2680 ± 2595 ng/mL (range, 635–10,191 ng/mL), whereas transferrin saturation 
ranged from 11.2 to 99.0% as severity of aceruloplasminemia corresponded with the severity of 
iron deficiency. Five patients, including those with aceruloplasminemia, were mildly anemic 
despite the iron overload. One of the 15 patients who had undergone a liver biopsy had 
exceptional liver histology, which was almost normal in structure and showed minimal iron 
overload in the Kupffer cells (Case 11). Six patients (Cases 1–4, 6, 7) had advanced fibrosis or 
cirrhosis associated with parenchymal or mixed iron overload of hepatocytes and Kupffer cells. 
In contrast to heavy iron deposits, one patient (Case 13) had mild portal fibrosis and 3 patients 
(Cases 8-10) were free from fibrosis in the liver. In addition, 8 patients had DM, while only 1 
patient had a triad of hemochromatosis of cirrhosis, DM, and pigmentation. 
The results of the genetic study, serum hepcidin-25 levels, and final diagnoses of the 
iron overload syndromes are summarized in Table 2. The patients with iron overload syndromes 
were divided into 2 groups. Ten patients had serum hepcidin-25 levels below the upper limit of 
the normal range of 20 ng/mL (low group; Cases 1–10),35, 36, 50 while 10 patients had a level 
higher than 40 ng/mL (high group; Cases 11–20). A statistically significant difference between 
the low and high hepcidin groups was also observed (7.4 ± 5.8 vs 138.6 ± 62.6 ng/mL; P < 0.01: 
Mann–Whitney test). This grouping was supported by another parameter of hepcidin/ferritin 
ratio that could be an iron regulatory hormone index adjusted by the representative body iron 
stores. The indices ranged between 0.05 and 16.0 x 10-3 in the low hepcidin group, and between 
19.6 and 148.8 x 10-3 in the high hepcidin group. The low hepcidin group included 3 Japanese 
(Cases 1–3) and 4 Italian (Cases 4–7) patients with non-HFE and HFE hemochromatosis, 
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respectively. Three Japanese aceruloplasminemic patients (Cases 8–10) had low serum 
hepcidin-25 levels similar to those found in hemochromatosis. 
The high hepcidin group included 2 families with ferroportin types A and B, respectively. 
The 49-year-old proband (Case 11) who exhibited selective iron overload in the 
reticuloendothelial cells, had a serum hepcidin-25 level of 42.5 ng/mL, while his 81-year-old 
father (Case 12) had a serum hepcidin-25 level of 155 ng/mL comparable with his high ferritin 
level of 2636 ng/mL. Another 66-year-old male patient (Case 13) of the second ferroportin 
disease family exhibited marked iron overload in the liver, which was first detected by CT 
imaging and later confirmed as heavy, mixed type-iron overload by biopsy. His serum 
hepcidin-25 level was 156.7 ng/mL and his serum ferritin level was also high (7980 ng/mL) with 
89.2% transferrin saturation. The remaining 7 patients in the high hepcidin group had a variety of 
iron overload syndromes. One patient with CRF and DM (Case 14) and 3 patients with CHC 
(Cases 15–17) showed high serum hepcidin-25 levels corresponding to the biochemical iron 
markers. Mild iron overload associated with a high serum hepcidin-25 level was found in a 
patient with ALD (Case 19). Two patients (Cases 16 and 20) with a history of repeated use of 
iron supplements also had high serum hepcidin-25 levels. The HFE, HJV, HAMP, TFR2, and 
SLC40A1 analyses on these 7 patients excluded a genetic basis for their iron overloads; therefore, 
we concluded that they all had acquired iron overload liver diseases. 
As shown in Figure 1, iron overload syndromes were clearly divided into two groups, 
but no correlations were observed between serum ferritin and hepcidin-25 levels in the high 
hepcidin group (p=0.096), nor low hepcidin group (p=0.349). Serum ferritin levels presented in 
a wide range (885–10,191 ng/mL), while all serum hepcidin-25 levels were below 20 ng/mL in 
the low hepcidin group. In contrast, both serum ferritin levels and hepcidin-25 levels in the high 
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hepcidin group presented in wide ranges of 635–7,980 ng/mL and 42.5–238.7 ng/mL, 
respectively.  
Responses to serum hepcidin-25 to iron removal by phlebotomy are indicated in Figure 
2. All patients responded similarly to the treatment, but differed in their serum hepcidin-25 levels. 
In 2 patients with TFR2 (Case 3) and HFE hemochromatosis (Case 5), pretreatment serum 
hepcidin-25 levels were low and declined slightly after treatment. In contrast, pretreatment serum 
hepcidin-25 levels were high and showed a marked reduction after treatment in the other 2 
patients with secondary iron overload syndromes (Cases 18 and 20).




 This is the first report describing serum hepcidin-25 levels in patients with a variety of 
iron overload syndromes to the best of our knowledge. Because genetic iron overload syndromes 
showed an ethnic difference with regard to prevalence,19, 37, 38 the patient population was 
intentionally expanded to a wider range than the general population. Four Italian patients with 
HFE hemochromatosis and 3 Japanese patients with aceruloplasminemia were included in the 
study with 13 Japanese patients with a variety of iron overload syndromes referred to 2 institutes 
in central Japan. Patients with chronic inflammations such as CRF, CHC, and rheumatoid 
arthritis as well as patients with mild anemia who were on iron supplements were included. 
However, patients with severe anemia and acute phase inflammation were excluded from the 
study because hepcidin synthesis is decreased by erythropoietic activity and increased by acute 
inflamation.8, 11 
Although this study with its small sample size appears preliminary, the iron overload 
syndromes in patients could still be divided into 2 phenotypes, one with high and the other with 
low hepcidinemia, both closely linked to their respective genotype; this information may thus be 
crucial prior to performing genetic analysis. This study suggests that low hepcidin groups include 
individuals with hemochromatosis and aceruloplasminemia, while high hepcidin groups include 
those with ferroportin disease and secondary iron overload syndromes. Hemoglobin, serum 
ferritin levels, and iron saturation of transferrin have their limitations as grouping variables for 
iron overload syndromes. The direct measurement of serum hepcidin-25 levels are consistent 
with the suppressed expression of hepcidin mRNA in the livers of patients with HFE 
hemochromatosis12 and measurements of the urinary output of hepcidin in patients with HJV 
hemochromatosis2 as well as TFR2 hemochromatosis.14 HAMP hemochromatosis could also be 
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classified in this group on detecting decreased urinary output of hepcidin in such patients.13 
Inadequate serum hepcidin levels and a response to phlebotomy similar to that observed in this 
study were reported for HFE hemochromatosis recently.16 
This is the first study of its kind to demonstrate low serum hepcidin-25 levels in patients 
with aceruloplasminemia. Similar presentations resulting from body iron overload, such as low 
hepcidin synthesis in the liver and low transferrin saturation are reported in ceruloplasmin 
knockout mice.39 Ceruloplasmin is a multicopper oxidase and plays a role in the mobilization 
and oxidation of iron from tissue stores with subsequent incorporation of ferric iron into 
transferrin.18, 19, 20 According to the iron sensor hypothesis of TFR2, increasing concentrations of 
iron-saturated transferrin increase TFR2 protein levels in hepatocyte by protecting the receptor 
from degradation. And consecutively, TFR2 would be expected to increase the association with 
HFE and to stimulate of hepcidin transcription.40, 41 This hypothesis suggests a crucial role of low 
iron saturation of transferrin in falsely signaling iron deficiency to the liver in patients with 
aceruloplasminemia. This results in suppressed synthesis and secretion of hepcidin into blood. 
Further studies are needed to clarify the involvement of a low-set hepcidin system in increased 
iron absorption in the gut of patients with aceruloplasminemia. 
 Serum hepcidin appears to be regulated at a higher level in patients with acquired iron 
overload syndromes than in the hemochromatosis group. Serum hepcidin levels were also 
adequately controlled in our patients with ferroportin disease type A and B. Age-dependent iron 
overload in the type A proband and his father (Cases 11 and 12) was associated with greater 
hyperhepcidinemia. These blood test results were consistent with findings in previous reports 
that measured urinary output of hepcidin.27 Serum hepcidin was 156.7 ng/mL in another patient 
(Case 13) whose liver histology was compatible with type B ferroportin disease. In patients with 
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type A disease, SLC40A1 mutations generate a protein that is defective in cell surface expression 
or loss of iron export function.42, 43, 44 In the less prevalent type B, the mutant gene generates 
proteins that show normal cell surface expression but reduced sensitivity to hepcidin.42, 43 The 
resistance of ferroportin to hepcidin might be the key not only to the iron overload of ferroportin 
disease, but also to the secondary iron overload syndromes. In fact, only 2 of the 7 patients had a 
history of repeated use of iron supplements followed by adequate hepcidin regulation. The 
increased serum hepcidin-25 levels appeared to have suppressed iron absorption in the gut. In 
patients with chronic diseases of the kidney, liver, and joints, the current state of 
hyperhepcidinemia might be induced by an iron overload and chronic inflammation, but the 
pathophysiologic processes leading to body iron accumulation during the long-term disease 
condition remain to be elucidated. Ferroportin proteins in the secondary iron overload syndromes 
may also be resistant to hepcidin, permitting persistent iron absorption in the gut. 
The involvement of the hepcidin system in iron regulation in CHC patients was unclear 
and thus much debated.15, 17, 45, 46 Three of our patients coinfected with HCV had a 
hepcidin-resistant iron overload syndrome without the evidence of a genetic basis for the latter. 
Establishing the serum hepcidin-25 levels35, 36, 47 might clarify complex issues related to 
ferroportin disease and the secondary iron overload syndromes. 
The pregenetic differential analysis of patients with iron overload syndromes should 
include the evaluation of ferritin, ceruloplasmin, and hepcidin-25 as 3 potential biochemical 
markers (Figure. 3). The first test should ideally determine serum ferritin levels. Then, the serum 
hepcidin-25 levels provide a guideline for a genetic study. Serum ceruloplasmin should be 
determined in the low hepcidin group to rule out a rare genetic disease with aceruloplasminemia. 
Aceruloplasminemia itself might be diagnostic, and further studies on hypohepcidinemia might 
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indicate a lifelong low-iron diet in either symptomatic or presymptomatic patients because of 
their intolerance of iron reduction therapy.48 For patients without aceruloplasminemia, gene 
analysis for hemochromatosis is highly recommended to confirm their genetic background. The 
primary target gene in Caucasians is HFE1, 37 and the secondary genes include TFR2, HJV, and 
HAMP. However, the primary target gene for non-Caucasians would be TFR233, 49 followed by 
HJV, HAMP, and HFE because HFE hemochromatosis is rarely present in other ethnic groups.37 
 As noted in our patients, a high regulatory hepcidin set-point suggests a diagnosis of 
ferroportin disease. Before final diagnosis of a secondary iron overload syndrome, genetic 
analysis of SLC40A1 is required. Without such a genetic study it is difficult to rule out the 
possible complication of this rare genetic disease with the more common, acquired iron overload 
syndromes. 
In conclusion, measurement of the serum hepcidin-25 levels has the potential for 
grouping patients with iron overload syndromes based on a newly proposed iron regulatory 
system. When combined with ferritin and ceruloplasmin levels, hepcidin-25 levels could be a 
potential test for the diagnosis of hemochromatosis and related disorders. 
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Table 1. The Clinical Features and Laboratory Data of Patients with Iron Overload Syndromes at Entry 









1*1 48/M HJV-hemochromatosis 6115 94.8 15.8 cirrhosis/P yes yes 
2*2 49/M TFR2-hemochromatosis 1057 93.5 13.8 fibrosis/P yes no 
3 40/M hemochromatosis 10191 94.2 14.0 fibrosis/mixed yes no 
4*3 55/M HFE-hemochromatosis 2141 94.0 15.6 cirrhosis/mixed no no 
5*3 33/M HFE-hemochromatosis 1821 92.0 13.8 chronic hepatitis/mixed no no 
6*3 65/F HFE-hemochromatosis 2204 87.0 15.2 cirrhosis/mixed no yes 
7*3 43/M HFE-hemochromatosis 3268 88.0 16.2 cirrhosis/mixed no yes 
8*4 59/F aceruloplasminemia 885 11.2 10.2 normal/mixed yes no 
9*4 55/F aceruloplasminemia 1035 14.6 9.4 normal/mixed yes no 
10*4 62/M aceruloplasminemia 1140 12.0 8.9 normal/mixed yes no 
11*5 49/M ferroportin disease type A 696 28.6 14.4 normal/RE no no 
12*5 81/M ferroportin disease type A 2636 88.3 13.4 no biopsy no no 
13 66/M hemochromatosis 7980 89.3 14.1 mild fibrosis/mixed yes no 
14 85/M CRF 1558 73.6 12.5 no biopsy yes no 
15 50/M CHC 635 95.5 14.3 chronic hepatitis/P no no 
16 42/F CHC and ISA 1270 50.8 11.1 no biopsy no no 
17 58/F CR of CHC to IFN 1721 61.8 13.8 chronic hepatitis/P no no 
18 60/F RA, hemochromatosis 4378 91.2 11.7 no biopsy no no 
19 64/M alcoholic cirrhosis 799 99.0 15.6 no biopsy no no 
20 33/F ISA 2076 91.1 12.6 normal/P no no 
Subtotal from Pt.1 to 10  (Mean±SD) 2986±2978 68.1±38.4 13.3±2.8    
Subtotal from Pt.11 to 20  (Mean±SD) 2375±2266 76.9±23.0 13.4±1.4    
Total  (Mean±SD) 2680±2595 72.5±31.2 13.3±2.1    
*1 Genetic study of the patient was reported in detail.30 
*2 Genetic study of the patient was reported in detail.29 
*3 Italian patient with HFE-hemochromatosis specially enrolled 
*4 Japanese patient with aceruloplasminemia specially enrolled 
*5 Genetic study of the patient was reported in detail.18 
Normal value of serum ferritin; male:26-310 ng/mL, female:7-110 ng/mL 
Normal value of transferrin saturation; 40-70% 
Normal value of hemoglobin; male:13.5-17.0 g/dL, female:11.2-14.5 ng/mL 
DM; diabetes mellitus 
M; male, F; female 
P; parenchymal, RE; reticuloendothelial, mixed; parenchymal and reticuloendothelial 
CRF; chronic renal failure 
ISA; iron supplement for anemia of unknown etiology 
CHC; chronic hepatitis C 
CR; complete responder 
IFN; interferon 
RA; rheumatoid arthritis 
 
Table 2. Results of Genetic Study, Serum Hepcidin Determination, and Final Diagnosis for Iron Overload Syndromes 






Final Diagnosis for 
Iron Overload Syndrome 
1 745G>C/745G>C in HJV*1 0.3 0.05 HJV-hemochormatosis 
2 1469T>G/1469T>G in TFR2*2 2.8 2.7 TFR2-hemochromatosis 
3 1100T>G/2008-9delAC in TFR2*3 12.2 1.2 TFR2-hemochromatosis 
4 845G>A/845G>A in HFE*4 3.0 1.4 HFE-hemochromatosis 
5 845G>A/845G>A in HFE 6.7 3.6 HFE-hemochromatosis 
6 845G>A/845G>A in HFE 4.1 1.9 HFE-hemochromatosis 
7 845G>A/845G>A in HFE 3.1 1.0 HFE-hemochromatosis 
8 607Ains/607Ains in Cp 10.3 11.6 aceruloplasminemia 
9 2630G>A/2630G>A in Cp*5 13.1 12.7 aceruloplasminemia 
10 1287TACACins/1287TACACins in Cp 18.2 16.0 aceruloplasminemia 
11 1467A>C/wt in SLC40A1*6 42.5 61.1 ferroportin disease type A 
12 1467A>C/wt in SLC40A1 155.0 58.8 ferroportin disease type A 
13 470A>C/wt in SLC40A1*7 156.7 19.6 ferroportin disease type B 
14 no mutations responsible 181.0 116.2 2nd iron overload in CRF and DM 
15 no mutations responsible 63.0 99.2 2nd iron overload in CHC 
16 no mutations responsible 189.0 148.8 2nd iron overload in CHC with iron supplement 
17 no mutations responsible 82.5 47.9 2nd iron overload in CHC 
18  no mutations responsible 238.7 54.5 2nd iron overload in RA 
19 no mutations responsible 105.5 132.0 2nd iron overload in alcoholic cirrhosis 
20 no mutations responsible 172.5 83.1 2nd iron overload with iron supplement 
Subtotal from Pt.1 to 10  (Mean±SD) 7.4±5.8 5.2±5.9  
Subtotal from Pt.11 to 20  (Mean±SD) 138.6±62.6 82.1±41.1  
Total  (Mean±SD) 73.0±80.0 43.7±48.7  
*1 The 745 G>C in HJV predicts D249H in HJV protein. 
*2 The 1469T>G in TFR2 predicts L490R in TFR2 protein. 
*3 The 1100T>G in TFR2 predicts L367R in TFR2 protein. 
*4 The 845G>A in HFE predicts C282Y in HFE protein. 
*5 The 2630G>A in Cp predicts W858ter in Cp protein. 
*6 The 1467A>C in SLC40A1 predicts R489S in ferroportin. 
*7 The 470A>C in SLC40A1 predicts D175A in ferroportin. 
 
CRF; chronic renal failure 
CHC; chronic hepatitis C 
DM; diabetes mellitus 
RA; rheumatoid arthritis 
Figure 1. Relationships between serum hepcidin-25 and ferritin levels of patients at entry. 
Patients with ferroportin disease and secondary iron overload (indicated by closed circles) 
showed high hepcidin-25 levels, whereas patients with hemochromatosis and 
aceruloplasminemia (indicated by open circles) demonstrated low serum hepcidin-25, 
irrespective of high serum ferritin levels. The figure indicates that patients with iron overload 
syndromes are clearly divisible into high and low hepcidin groups. However, any correlations are 
not observed between serum hepcidin-25 level (y) and ferritin level (x) in the high hepcidin 
group (y = 0.013x + 108, r = 0.46), nor in the low hepcidin group. 
 
Figure 2. Reduction of serum hepcidin-25 levels after phlebotomy.  
Two patients each in the low hepcidin and high hepcidin groups responded similarly to 
phlebotomy treatment, but differ in serum hepcidin-25 levels. Serum hepcidin-25 levels are low 
in patients with hemochromatosis (Cases 3, 5) but high in patients with secondary iron overload 
syndromes (Cases 18, 20). Serum ferritin level in indicated in parentheses as ng/mL. 
 Figure 3. A proposed differential diagnosis of iron overloads syndromes. 
Serum hepcidin levels provide a guideline for the genetic study of iron overload syndromes. The 
first step in differential diagnosis might be to divide the patients into 2 groups with low and high 
serum hepcidin-25 levels, respectively. The low hepcidin group includes patients with 
hemochromatosis and a rare aceruloplasminemia, while the high hepcidin group consists of 
patients with ferroportin disease and acquired iron overload syndromes. Determination of serum 
ceruloplasmin might be needed before a genetic study of hemochromatosis. Aceruloplasminemia 
may be suspected from specific clinical features and direct determination of serum ceruloplasmin 
before hepcidin measurement. In patients with hyperhepcidinemia, genetic analysis for SLC40A1 
is needed before the final diagnosis for secondary iron overload syndromes. The primary target 
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